Related Experiment Video
Updated: Apr 25, 2026
08:29
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
14.0K
Adult prostate sarcoma: the Memorial Sloan Kettering experience
John E Musser1, Melissa Assel2, Joseph W Mashni1
1Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Urology
|August 30, 2014
Summary
Adult prostate sarcoma has a poor prognosis, particularly when diagnosed with metastasis. Rhabdomyosarcoma histology is linked to worse cancer-specific survival (CSS) than leiomyosarcoma.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Prostate sarcoma is a rare and aggressive malignancy.
- Understanding prognostic factors is crucial for patient management.
Purpose of the Study:
- To analyze the institutional experience with adult prostate sarcoma over three decades.
- To identify factors associated with cancer-specific survival (CSS).
Main Methods:
- Retrospective review of 38 adult prostate sarcoma cases (1982-2012).
- Univariate Cox proportional hazards regression analysis.
- Evaluation of tumor size, histology, AJCC stage, and metastasis at diagnosis.
Main Results:
- Rhabdomyosarcoma histology showed significantly poorer CSS compared to leiomyosarcoma.
- Median CSS was 2.9 years; 7.7 years for localized disease, 1.5 years for metastatic disease.
- No significant association found between tumor size and CSS.
Conclusions:
- Adult prostate sarcoma carries a poor prognosis, especially with metastatic disease.
- Surgery is standard but offers limited benefit for metastatic or consolidated disease.
- Histology, particularly rhabdomyosarcoma, is a key prognostic indicator.
